Sino Biological announced the expedited availability of research reagents for Nipah virus (NiV) to support vaccine and diagnostic development globally. The company said it is expanding production and distribution of proteins, antibodies and assay tools aimed at enabling preclinical studies and assay validation for NiV countermeasures. The reagents aim to lower technical barriers for academic and industry teams working on NiV vaccines and diagnostics, creating standardized inputs for neutralization assays and antigen design. Sino Biological framed the launch as part of preparedness work for high‑consequence zoonotic pathogens, and the offering should accelerate preclinical screening and assay harmonization across labs.